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The putative proteasome-associated proteins Mpa
(Mycobaterium proteasomal ATPase) and PafA (protea-
some accessory factor A) of the human pathogen
Mycobacterium tuberculosis (Mtb) are essential for viru-
lence and resistance to nitric oxide. However, a direct link
between the proteasome protease and Mpa or PafA has
never been demonstrated. Furthermore, protein degrada-
tion by bacterial proteasomes in vitro has not been accom-
plished, possibly due to the failure to find natural
degradation substrates or other necessary proteasome co-
factors. In this work, we identify the first bacterial prot-
easome substrates, malonyl Co-A acyl carrier protein
transacylase and ketopantoate hydroxymethyltransferase,
enzymes that are required for the biosynthesis of fatty
acids and polyketides that are essential for the pathogen-
esis of Mtb. Maintenance of the physiological levels of
these enzymes required Mpa and PafA in addition to
proteasome protease activity. Mpa levels were also regu-
lated in a proteasome-dependent manner. Finally, we
found that a conserved tyrosine of Mpa was essential for
function. Thus, these results suggest that Mpa, PafA, and
the Mtb proteasome degrade bacterial proteins that are
important for virulence in mice.
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Introduction
Most individuals who are infected with Mycobacterium
tuberculosis (Mtb) do not develop tuberculosis. In these
cases, the immune system is able to prevent the bacteria
from growing uncontrollably. However, despite effective con-
trol of Mtb growth in healthy individuals, Mtb is rarely
sterilized from the body (Hernandez-Pando et al, 2000).
Mtb resides primarily in macrophages, a cell type that
normally controls bacterial growth. Although numerous as-
pects of the immune system are responsible for slowing the
growth of Mtb, increasing data suggest that nitric oxide (NO)
is essential for this process (Nozaki et al, 1997; MacMicking
et al, 1997b; Bekker et al, 2001; Chan et al, 2001; Scanga et al,
2001; Jung et al, 2002). NO, which can form other reactive
nitrogen intermediates (RNI), has antimicrobial activity and
is produced by the inducible nitric oxide synthase (iNOS) in
macrophages and other cell types (MacMicking et al, 1997a).
Genetic inactivation of iNOS in mice results in severe sus-
ceptibility to Mtb; iNOS/ mice succumb rapidly after
infection with wild type (WT) Mtb (40–80 days)
(MacMicking et al, 1997b; Mogues et al, 2001; Scanga et al,
2001; Darwin et al, 2003). In contrast, WT mice live more
than a year after infection with WT Mtb.
In an effort to identify new targets for tuberculosis therapy,
over 10 000 Mtb mutants were screened for hyper-suscept-
ibility to the lethal effects of NO and other RNI (Darwin et al,
2003). This screen identified Mycobacterium proteasomal
ATPase (Mpa), which forms hexameric ATPase rings, and
proteasome accessory factor A (PafA), a protein of unknown
function (Darwin et al, 2003, 2005). Because Mpa and PafA
are encoded in proximity to the Mtb proteasome genes (prcA
and prcB) and Mpa is homologous to ATPases found in the
regulatory cap of the eukaryotic 26S proteasome, these
proteins were presumed to be involved in proteasome func-
tion (Nagy et al, 1997).
Proteasomes are present in all eukaryotes and archaea, and
in some bacteria of the class Actinomycetes, which includes
Mtb (Butler et al, 2006). The proteasome is a multisubunit,
ATP-dependent protease and is the major cytosolic protein
degradation structure in eukaryotic cells (Baumeister et al,
1998). 20S proteasome core particles are composed of two
rings of catalytic b-subunits sandwiched by rings of a-sub-
units that form a barrel-shaped structure. Access to the
channel and the catalytic sites of the b-subunits is obstructed
by a gate formed by the a-subunits (Groll et al, 1997; Unno
et al, 2002; Benaroudj et al, 2003; Hu et al, 2006; Lin et al,
2006). The eukaryotic 26S proteasome is composed of the 20S
core particle and one or two 19S regulatory caps. The cap is
composed of numerous proteins, including six AAA (ATPases
associated with various activities) ATPases, and is involved in
the recognition, unfolding, and translocation of ubiquitinated
proteins into the 20S proteasome core (Pickart and Cohen,
2004). It is not known how proteins are targeted for degrada-
tion in prokaryotes where 19S regulatory caps and ubiquitin
appear to be absent. Attempts to demonstrate ATPase-depen-
dent degradation of proteins by bacterial proteasome cores
in vitro have not been successful (our unpublished data)
(Wolf et al, 1998), most likely due to the lack of additional co-
factors required for protein degradation.
Little is known about bacterial proteasome biology.
Questions that remain to be answered include those regard-
ing the role of proteasomes in bacteria, the requirement of
cofactors for proteasome function, and the mechanism by
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which substrates are targeted for degradation by the protea-
some. In this work, we identify the first natural substrates of
a bacterial proteasome that will allow us to begin to address
these questions.
Results
The C-terminus of Mpa is essential for Mtb virulence
and resistance to RNI
Earlier studies described mpa607, a mutant with a transposon
insertion in the penultimate codon, which caused the dele-
tion of the last two amino acids: tyrosine and leucine (Darwin
et al, 2003). It was previously determined that Mpa forms a
hexameric AAA ATPase that is homologous to proteasomal
ATPases (Darwin et al, 2005). Mpa607 retains the ability to
hydrolyze ATP in vitro (Darwin et al, 2005). Notably, the
mpa607 strain was as sensitive to RNI in vitro as the mpa null
strain, suggesting that the terminal amino acids are essential
for the function of Mpa in RNI resistance (Darwin et al, 2003,
2005).
It was reported that the mpa607 mutant was attenuated in
mice, as determined by enumerating colony-forming units
(CFU) from the lungs and spleens 8 weeks after infection
(Darwin et al, 2003). Since that study, we have determined
that WT mice and mice deficient for iNOS live significantly
longer when infected with the mpa607 mutant compared to
infection with WT Mtb (Figure 1A). WT mice infected with
the mpa607 strain of Mtb had a 60% survival rate after one
and a half years, whereas those infected with WT Mtb only
had a 20% survival rate (Figure 1A). Importantly, WT mice
that had been infected with any of the mutant strains of Mtb
were killed around 600 days after infection for reasons other
than tuberculosis; these mice exhibited symptoms of aging,
including tumors and perturbed walking, but were otherwise
maintaining robust body weight and active movement (not
shown). In contrast, WT mice infected with WT Mtb were
hunched, thin, ruffled, slow-moving and had labored breath-
ing, which are typical symptoms of mice succumbing to Mtb
infection (not shown). Although genetic inactivation of iNOS
resulted in increased susceptibility of the mice to Mtb, the
mpa607 mutant was still severely attenuated in these mice
compared to the WT Mtb strain (Figure 1A). Similar effects
were seen when mice were infected with the pafA null strain
of Mtb (Figure 1A) or the mpa null strain (Darwin et al,
2005). This outcome demonstrates that, like the mpa null
strain (Darwin et al, 2005), the mpa607 and the pafA null
strains are highly attenuated in the mouse model of Mtb
infection and support the hypothesis that Mpa and PafA
operate in a common pathway. Additionally, these experi-
ments indicate that the C-terminus of Mpa is essential for
Mpa function.
Because the truncation in Mpa607 drastically impaired the
virulence of Mtb, we sought to define the functional rele-
vance of the missing residues. We aligned the WT Mpa
sequence with the sequences of other proteasome-associated
ATPases to determine if any of the C-terminal amino acids
were conserved. We found that the penultimate tyrosine of
Mpa was conserved across all proteasome-bearing bacteria,
most archaea, and some of the ATPase subunits of the
eukaryotic 19S cap (Figure 1B). The conservation of the
penultimate tyrosine across all domains of life suggested
that this residue is important for the proper functioning of
these proteasome-associated molecules.
We mutagenized the conserved penultimate tyrosine to
determine if it was essential for Mpa function. We substituted
the tyrosine with phenylalanine (MpaY608F) to test if a
closely related amino acid would affect Mpa function.
Additionally, we mutated the tyrosine to glutamic acid
(MpaY608E) to introduce a negative charge that can mimic
constitutive tyrosine phosphorylation. This strategy was
based on reports that the related eukaryotic ATPase Cdc48
(p97/valosin-containing protein) was determined to be phos-
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Figure 1 The C-terminus of Mpa is essential for Mtb virulence and
resistance to RNI. (A) Survival of WT and iNOS/ C57BL/6 mice
infected with WT, mpa607 and pafA strains of Mtb. Each data point
represents the percentage of mice that were alive at the time point
shown on the x axis. (B) Alignment of the C-terminus of Mpa with
the C-termini of proteasome-associated ATPases from representative
actinomycetes, archaea and yeast. The conserved penultimate
tyrosines are highlighted. Sequences were compiled from the
NCBI server. (C) Substitution of the penultimate tyrosine of Mpa
abolished protection against RNI in Mtb and increased the steady-
state levels of Mpa protein. (Top) Each data point represents the
average of triplicate samples. These results are representative of
at least three independent experiments. Error bars represent þ s.d.
(Middle) (Bottom) Immunoblot analysis of Mpa, PafA and DlaT
(dihydrolipoamide acyltransferase, loading control) in Mtb lysates
from the same cultures harvested just prior to the nitrite survival
assay.
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phorylated on the penultimate tyrosine; mutagenesis of this
tyrosine to glutamate resulted in Cdc48 that behaved as if it
were constitutively phosphorylated (Egerton et al, 1992;
Madeo et al, 1998).
The mpa point mutant plasmids were introduced indivi-
dually into the mpa null strain of Mtb on an integrative
plasmid. Both mpaY608 alleles failed to protect Mtb against
RNI in vitro (Figure 1C). Notably, the mpaY608F Mtb strain
was as vulnerable to RNI as the mpa null strain, despite
replacement of the penultimate tyrosine with another aro-
matic amino acid (Figure 1C). The mpaY608E Mtb strain was
also as susceptible to RNI as the mpa null strain (Figure 1C),
suggesting that phosphorylation of the tyrosine is not
important for Mpa-dependent protection against RNI.
Consistent with this hypothesis, phosphotyrosine immuno-
blot analysis of Mtb lysates did not detect tyrosine-phos-
phorylated Mpa (data not shown).
Because the Mtb strains expressing the mutant mpa alleles
were as sensitive to RNI as the mpa null strain, we checked
for the presence of the MpaY608-mutant proteins with anti-
bodies against Mpa. The mutant proteins were observed at
higher steady-state levels than those seen in WT Mtb or the
mpa null strain complemented with WT mpa (Figure 1C)
(Darwin et al, 2005). We also examined PafA levels in these
strains. PafA was present at slightly increased levels in the
mpa null mutant but not in the penultimate tyrosine mutants
or the mpa complemented strain (Figure 1C). It is not clear if
the increased amount of PafA in the mpa null strain is
significant in light of the observation that PafA levels appear
WT in the other Mpa-defective strains.
Taken together, these data show that the extreme C-term-
inal residues of Mpa, particularly the highly conserved
tyrosine, are indispensable for Mpa function. Furthermore,
the results suggest that the same residues are important for
the maintenance of WT steady-state protein levels of Mpa.
Mpa and PafA work with the Mtb proteasome to
regulate Mpa protein levels
The accumulation of the MpaY608-mutant proteins was not
entirely unexpected because previous analysis revealed ele-
vated levels of the Mpa607 protein in the mpa607 mutant
(Darwin et al, 2005). Additionally, studies of Mpa with
mutations in the ATPase catalytic site demonstrated increased
steady-state levels of Mpa (Darwin et al, 2005). These data
suggested that the process that regulates Mpa protein levels
requires the penultimate tyrosine and ATPase activity of Mpa.
Because both Mpa and PafA are thought to be involved in a
common pathway, we also tested whether endogenous Mpa
levels were affected in the pafA null strain. The pafA null
strain showed increased abundance of Mpa (Figure 2A)
comparable to that seen in the Mtb strains expressing the
MpaY608 point mutants (Figure 1C) or the Mpa catalytic site
mutants (Darwin et al, 2005). Taken together, these results
further establish a link between Mpa and PafA and suggest
that Mpa protein levels are regulated by a mechanism that
requires at least Mpa and PafA.
Proteasome-associated ATPases mediate the entry of pro-
tein substrates into the catalytic chamber of the proteasome
(Kohler et al, 2001a; Smith et al, 2005). It has been suggested
that the C-termini of these ATPases are important for opening
the gate of the proteasome core (Forster et al, 2005). These
findings, in conjunction with the differences in Mpa protein
levels observed in the various mpa mutant strains, led us to
the hypothesis that Mpa stimulates gate opening of the Mtb
proteasome core and promotes its own turnover. If Mpa were
a substrate of the proteasome, then Mpa protein levels would
increase in the absence of proteasome protease activity.
We inhibited the Mtb proteasome in cultures treated with
epoxomicin, a specific eukaryotic proteasome inhibitor that is
effective against the Mtb proteasome (Kisselev and Goldberg,
2001; Darwin et al, 2003; Lin et al, 2006) and assessed Mpa
levels in Mtb. Consistent with our hypothesis, Mpa protein
was more abundant in a WT strain that had been treated with
proteasome inhibitor than in a WT strain incubated with
nothing or the vehicle control (Figure 2B). In contrast, the
levels of the proteolytic b-subunit of the Mtb proteasome,
PrcB, or the loading control protein dihydrolipoamide acyl-
transferase (DlaT) remained constant (Figure 2B). This find-
ing demonstrates that the proteasome-dependent regulation
of Mpa was specific. Quantitative real-time PCR (QRTPCR)
showed that there were no changes in mpa transcript levels
between the WT strain incubated with or without epoxomicin
(Figure 2C), suggesting the regulation of Mpa protein levels
occurs post-transcriptionally.
Taken together, the findings of these experiments are the
first to link Mpa and PafA to proteasome protease activity.
Moreover, this activity appears to regulate the steady-state
levels of a specific protein, Mpa, the presumptive protea-
some-associated ATPase. To our knowledge, this is also the
first demonstration that proteasomal ATPase levels can be
autoregulated by the proteasome pathway.
FabD and PanB levels are regulated by the Mtb
proteasome in an Mpa- and PafA-dependent manner
As Mpa protein levels were regulated by the concerted efforts
of Mpa, PafA and the Mtb proteasome, we hypothesized that
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Figure 2 Mpa protein levels are regulated by the Mtb proteasome.
(A) Anti-Mpa immunoblots of whole-cell lysates from a WTand the
pafA null strain of Mtb. Both strains contain pMV306, the empty
vector used for complementation analysis. DlaT shows equivalent
loading. (B) (Top) Anti-Mpa immunoblots of whole-cell lysates
from WT Mtb and WT Mtb that had been incubated with DMSO
or 50mM of the proteasome inhibitor epoxomicin in DMSO.
(Middle) Anti-PrcB immunoblots of the same samples. (Bottom)
Immunodetection of DlaT was used as a loading control for both
experiments. (C) QRTPCR analysis of mpa transcript levels in WT
Mtb that had been incubated with either DMSO or 50mM epoxomi-
cin in DMSO. The copy number of each transcript was normalized
to a non-differentially regulated RNA, rpoB for each strain tested.
Values represent two biologically replicate RNA samples.
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Mpa is necessary for the proteasome-dependent degradation
of other protein substrates in Mtb. To search for other natural
proteasome substrates in Mtb, we compared the steady-state
proteomes of WTand mpa null strains using two-dimensional
(2D) gel electrophoresis. Global changes in protein levels
were not observed between the WT and mutant strains;
however, this could have been due to the limit of sensitivity
of 2D gel analysis. Two proteins were reproducibly more
abundant in gels prepared with lysates from the mpa null
strain when compared to gels prepared from WT strains
(Figure 3A). This was observed whether the strains were
grown under standard conditions or in acidified media with
or without nitrite (Figure 3A). The two proteins were identi-
fied by matrix assisted laser desorption/ionization-time of
flight (MALDI-TOF) analysis as malonyl Co-A acyl carrier
protein transacylase (FabD) (Kremer et al, 2001) and keto-
pantenoate hydroxymethyltransferase (PanB) (Chaudhuri
et al, 2003; Sugantino et al, 2003).
To determine if the difference in protein levels was due to
an increase in fabD or panB transcripts in the mpa mutant,
we analyzed the transcript levels of both genes by QRTPCR.
There were no statistically significant increases in fabD or
panB transcripts in the mpa null strain compared to the WT
strain, demonstrating that the increased abundance of FabD
and PanB in the mpa mutant was not due to amplified gene
expression (Figure 3B).
To test the hypothesis that FabD and PanB are Mtb protea-
some substrates, we examined steady-state FabD and PanB
protein levels in proteasome protease inhibited WT Mtb.
Similar to the proteome of the mpa null strain, endogenous
FabD (as confirmed by MALDI-TOF) and presumed PanB
spots were increased in intensity in proteasome-inhibited
samples compared to untreated WT Mtb samples
(Figure 3A, far right). There was no statistically significant
change in the panB transcript between the treated and
untreated WT Mtb strains; however, this was not the case
for fabD (Figure 3B). Expression of fabD was reduced 50–
60% in epoxomicin treated cultures (P¼ 0.0002; Student’s
unpaired t-test). One possible explanation is that the accu-
mulation of FabD results in increased amounts of long-chain
fatty acid intermediates in the cell that exert a negative effect
on fabD expression. This form of gene control is well
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Figure 3 FabD and PanB are candidate substrates of the Mtb proteasome. (A) 2-D gel electrophoresis of total lysates from untreated WT Mtb
compared to mpa mutant Mtb and WT Mtb incubated with the proteasome inhibitor epoxomicin. Spots corresponding to FabD and PanB are
circled. The 2-D gels were prepared with filtered total cell lysates from the Mtb strains and separated by isoelectric focusing on a pH 4–8
gradient in the first dimension and 10% SDS–PAGE in the second dimension. Only the portion of the gels that showed reproducible differences
is shown. Proteins were visualized by silver staining and the relevant spots were identified by MALDI-TOF. Spots corresponding to FabD and
PanB were observed in at least four different paired samples by 2D gel analysis. Nine peptides representing 44% coverage of FabD and six
peptides representing 37% coverage of PanB were identified. (B) QRTPCR analysis of fabD and panB transcript levels. The copy number of each
transcript was normalized to non-differentially regulated rpoB. Values are shown as copy number per 10 000 copies of rpoB and represent two
biologically replicate RNA samples. The differences in the transcript values for fabD and panB between the WT and mpa strains were not
statistically significant as determined by unpaired t-tests (P40.05). The two- to three-fold difference in fabD expression after epoxomicin
treatment is statistically significant (P¼ 0.0002). (C) Anti-FLAG immunoblots of whole-cell lysates to examine the steady-state protein levels of
epitope-tagged versions of FabD and PanB in untreated WT, mpa null, pafA null and proteasome-inhibited WT Mtb strains. WT Mtb was
incubated with 50 mM epoxomicin in DMSO to inhibit proteasome protease activity. Immunodetection of DlaT is shown as a loading control.
(D) Anti-FLAG immunoblots of whole-cell lysates to examine the steady-state protein levels of recombinant DlaT in untreated WT, mpa null
and pafA null Mtb strains. Equivalent cell numbers were analyzed.
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characterized for the fad/fab genes of Escherichia coli (Raman
and DiRusso, 1995; Raman et al, 1997), but it is not known if
a similar mechanism occurs in Mtb. Furthermore, it is not
clear why this would occur in epoxomicin treated samples
and not in the mpa mutant. Nonetheless, this result empha-
sizes the observation that FabD protein levels are not
increased due to an increase in fabD transcription in the
proteasome-defective strains.
We validated the results seen on the 2-D gels by using
immunoblotting to follow changes in the levels of epitope-
tagged versions of FabD and PanB in recombinant strains
of Mtb. WT, mpa and pafA strains of Mtb were transformed
with plasmids encoding FLAG-fabD-His6 and FLAG-panB-His6
cloned downstream of a heterologous Mycobacterium bovis
Bacille Calmette-Guerin hsp60 promoter (Scholz et al, 2000)
and an E. coli ribosome binding site. Anti-FLAG immunoblots
of total cell lysates revealed a dramatic increase in the steady-
state levels of the FLAG-tagged proteins in the mpa and pafA
mutant strains compared to WT Mtb (Figure 3C). This further
strengthened the functional association between Mpa and
PafA. We also observed increased levels of the recombinant
proteins in a WT strain that had been incubated with protea-
some inhibitor (Figure 3C). In contrast, the recombinant
proteins were barely detectable in the untreated WT strain,
consistent with the results of the endogenous proteins ob-
served by 2D gel analysis (Figure 3C).
In contrast to FabD and PanB, epitope-tagged DlaT protein
was equally abundant in the WT and mutant Mtb strains
(Figure 3D). These data suggest that the accumulation of
recombinant FabD and PanB in the mutant strains was due to
intrinsic features of these proteins, rather than experimental
artifact. Furthermore, the design of the heterologous expres-
sion system controls for possible changes in transcription and
translation initiation rates, supporting the hypothesis that the
recombinant protein levels were increased because the pro-
teins were not efficiently degraded. Therefore, FabD and PanB
steady-state levels, like those of Mpa, are regulated in Mtb by
a pathway that requires Mpa, PafA and proteasome protease
activity.
We assessed the potential effects the accumulation of FabD
and PanB might have on several important fatty acids.
Mycolic acid methyl esters, fatty acid methyl esters, methy-
lated lipids, triacyl glycerols, and wax esters in WT, mpa,
mpa-complemented and pafA strains were examined. All of
these molecules appeared to be normal in mpa and pafA
mutant strains (Supplementary Figure S1). However, we
cannot rule out other effects that are not detectable by even
these extensive assays. We also observed that the mpa
mutant consistently appeared to have reduced uptake of
palmitic acid (Supplementary Figure S1C and D), whereas
uptake looked WT in the complemented and pafA strains. We
do not yet understand the significance of this phenomenon.
Despite this observation, our analysis suggests that there are
no dramatic changes in the fatty acid and lipid profiles of mpa
and pafA mutants.
The C-terminus of Mpa is required for maintaining
wild-type steady-state levels of FabD and PanB
The C-terminal Mpa mutants were unable to maintain WT
Mpa protein levels, suggesting a loss of function of Mpa.
Therefore, we determined whether or not the two amino acid
truncated form of Mpa was able to regulate the protein levels
of the newly discovered candidate substrates. We examined
the steady-state protein levels of FLAG-FabD-His6 and FLAG-
PanB-His6 in the mpa607 strain. Anti-FLAG immunoblots
revealed increased levels of FLAG-FabD-His6 and FLAG-
PanB-His6 in the mpa607 strain compared to WT Mtb
(Figure 4), similar to the increases seen in the mpa null
and pafA null strains of Mtb (Figure 3C). The inability of
Mpa607 to regulate the recombinant protein levels further
suggests that the C-terminal residues are essential for Mpa to
function in the proteasome degradation pathway.
Discussion
Mpa, PafA and the Mtb proteasome were previously linked to
each other because of their ability to provide resistance to
RNI in Mtb (Darwin et al, 2003). In addition, both mpa and
pafA mutant strains of Mtb are similarly attenuated in mice,
suggesting that both Mpa and PafA participate in a common
pathway needed for in vivo survival. We further substantiate
this association with the discovery that Mpa, PafA and the
proteasome are involved in the regulation of FabD, PanB and
Mpa protein levels. Mpa and PafA are equally important in
maintaining physiologic levels of FabD and PanB because the
amounts of these proteins are similarly affected in mpa and
pafA mutant strains. The inability to regulate Mpa protein
levels in the absence of pafA or in proteasome protease-
inhibited WT Mtb further provides evidence that Mpa, PafA
and the proteasome core are functionally linked. Thus, we
propose a model that suggests Mpa interacts with the protea-
some core in a PafA-dependent manner to promote the
degradation of proteins such as FabD, PanB and Mpa itself
(Figure 5).
In order to conclude that the Mtb proteasome degrades
FabD, PanB and Mpa, it will be necessary to reconstitute the
proteasomal system in vitro. Proteolysis of peptide substrates
by the Mtb 20S proteasome has been demonstrated in vitro
(Lin et al, 2006). However, this process is not comparable to
proteolysis of a globular substrate; accessory factors, such as
an ATPase, are not required to promote peptide degradation.
Previous attempts to reconstitute degradation of a folded
protein by the homologous Rhodococcus erythropolis protea-
some system in vitro with 20S proteasome cores and the
ATPase ARC have been unsuccessful (Wolf et al, 1998). This
is not surprising because we found that the Mtb proteasome
system requires at least two co-factors, Mpa and PafA, in
addition to the proteasome core to regulate the levels of
WT mpa
mpa
607 WT mpa
mpa
607
FLAG-FabD-His6 FLAG-PanB-His6
FLAG
DlaT
Mtb strain:
Figure 4 The C-terminus of Mpa is necessary to promote the
apparent proteasome-dependent degradation of FabD and PanB.
Anti-FLAG immunoblots of whole-cell lysates to examine the stea-
dy-state protein levels of epitope-tagged versions of FabD and PanB
in WT, mpa null, mpa607 Mtb strains. Immunodetection of DlaT is
shown as a loading control.
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candidate substrates. So far, direct interactions between Mpa,
PafA and the proteasome core have not been detected, most
likely due to the lack of other co-factors required for protein–
protein contacts (MJ Pearce and KH Darwin, unpublished
results). We are currently working to determine if proteaso-
mal degradation of endogenous substrates requires additional
co-factors in Mtb.
Our genetic analysis suggests that a truncation at the
C-terminus of Mpa prevents the proteasome-dependent de-
gradation of FabD, PanB and Mpa. A possible explanation for
these results is that the C-terminus of Mpa is essential for
opening the gate of the Mtb 20S proteasome. Studies in other
organisms employing proteasomal ATPase and proteasome
gate mutants suggest that the ATPases are responsible for
activating 20S proteasomes by opening the gate to allow
access to the site of proteolysis in the core particle (Groll
et al, 1997; Kohler et al, 2001b; Benaroudj et al, 2003; Smith
et al, 2005). The importance of the ATPase C-terminus in
proteasome gate opening is supported by a finding that C-
terminal truncation of the archaebacterial ATPase proteasome
activating nucleotidase prevented it from degrading casein in
vitro (Forster et al, 2005). In an analogous bacterial degrada-
tion system, the C-terminus of the ATPase HslU (ClpY) is
required for the activation of the HslV (ClpQ) protease. The
binding of ATP to HslU induces a conformational change in
its C-terminus that allows the C-terminus to interact with
pockets inside the HslV protease causing an opening of the
HslV entry pore (Wang et al, 2001; Seong et al, 2002).
Together, these studies establish a theme that the C-termini
of protease-associated ATPases are critical for the interaction
with and the activation of their partner proteases, and our
data indicate that the same might be true for the activation of
the Mtb proteasome by Mpa. Interestingly, the amino-acid
substitution in MpaY608F leaves an aromatic ring missing a
hydroxyl group that is present in the usual tyrosine side
chain. This missing hydroxyl group may be important for
forming hydrogen bonds with residues in the Mtb proteasome
a-subunits that stabilize the interaction of Mpa with the
proteasome.
Eukaryotic proteasomes contribute to the regulation of
many cellular processes by degrading proteins (Coux et al,
1996), but there is little data regarding how the 26S protea-
some components are themselves turned over (Chen and
Hochstrasser, 1996; Schmidtke et al, 1996; Hirano et al,
2005). Our results indicate that Mpa, the proposed protea-
some-associated ATPase, is itself degraded by the Mtb protea-
some. Studies of the Clp protease in Gram-negative bacteria
have revealed that the ClpA ATPase is a substrate of the ClpP
protease, a situation that resembles our observation with Mpa
(Maurizi et al, 1990). In the Clp system, either the ClpA or
ClpX ATPase associates with ClpP to direct the degradation of
particular substrates (Gottesman, 2003). It is possible that the
degradation of ClpA by ClpP quickly resets the protease
system to allow interactions with ClpX. It is tempting to
speculate that a similar situation might apply to Mtb because
Mpa is not essential for normal growth in vitro, while the
proteasome protease genes are predicted to be essential or
required for optimal growth (Darwin et al, 2003; Sassetti et al,
2003). Perhaps, there are additional ATPase regulators of the
proteasome in Mtb that function in protein turnover.
FabD and PanB are involved in fatty acid metabolism and
FabD is also required for polyketide synthesis. About 6% of
the Mtb genome (B250 genes) is devoted to the metabolism
of fatty acids, suggesting that these macromolecules are
important for the mycobacterial lifestyle (Kinsella et al,
2003). So far, the fatty acid profiles of the mutant strains
appear to be normal; however, we cannot rule out that
changes are occurring in the mutant strains. Importantly,
we do not believe that the accumulation of these enzymes
is necessarily responsible for the attenuation of the mpa and
pafA mutants.
Although our proteomic analyses identified two putative
substrates, it is likely that more exist. We are currently
exploring other methods to identify additional proteins that
are regulated by the Mtb proteasome with the hope that their
discovery will help us understand how proteins are targeted
for proteolysis. Furthermore, identification of these substrates
may reveal why the mpa and pafA mutants are attenuated
in vivo.
This work has identified the first putative natural sub-
strates of a prokaryotic proteasome. These proteins will be
useful tools as we continue to study Mpa, PafA and the Mtb
proteasome in their involvement in cellular protein degrada-
tion and virulence. Furthermore, we have described the
essentiality of the extreme C-terminus of Mpa for protea-
some-dependent regulation of protein levels, and we have
elucidated an auto-regulatory circuit involving proteasome-
associated factors. Most importantly, we have provided the
first compelling evidence that Mpa, PafA and the Mtb protea-
some core protease function to regulate protein levels in Mtb.
We favor the hypothesis that Mpa and PafA work directly
with the proteasome to promote the degradation of target
proteins; however, other mechanisms of regulation may exist.
Regardless of the underlying mechanism, a better under-
standing of the biology of the Mtb proteasome and the
characterization of its substrates may provide new targets
for the treatment of tuberculosis.
Materials and methods
Bacterial strains, growth conditions and primers
The bacterial strains, plasmids and primers used in this study are
listed in Table I. All primers were purchased from Invitrogen. Mtb
strains were grown in Middlebrook 7H9 broth (Difco) supplemented
with 0.2% glycerol, 0.05% Tween-80, 0.5% bovine serum albumin,
0.2% dextrose and 0.085% sodium chloride (ADN). Cultures were
grown without shaking in either 25 or 75 cm2 vented flasks
(Corning) in humidified incubators with 5% CO2 at 371C. 7H11
agar (Difco) supplemented with oleic acid, albumin, dextrose and
FabD, PanB or
Mpa monomer
COOH
Mpa
C
Proteasome core
C
Degraded 
substrate
PafA
C
Other factors? PrcB
PrcA
Figure 5 Proposed model of the Mtb proteasome. The C-termini of
Mpa hexamers may interact with the PrcA subunits, thereby pro-
moting opening of the gate formed by the PrcA N-termini and
allowing access into the proteolytic core. Interactions of Mpa with
the protease core (b-subunit¼PrcB; a-subunit¼PrcA) appear to
require the presence of PafA. Direct interactions between substrates,
Mpa, PafA and the proteasome core have not yet been detected,
possibly due to the requirement of additional factors.
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catalase (BBL) was used for growth on solid medium. The
antibiotics kanamycin and hygromycin were each used at a
concentration of 50mg ml1 as needed. For epoxomicin experi-
ments, cultures were grown in 7H9þADN to an OD580 of B0.5
after which either a final concentration of 50 mM epoxomicin in
DMSO (Boston Biochem) or an equal volume of DMSO was added.
Cultures were harvested 4 days after addition of the compound as
described below.
Plasmids and site-directed mutagenesis
WTand mutant forms of mpa were expressed from pMV306 (HygR),
which integrates into the attB site on the Mtb chromosome. For site-
directed mutagenesis of pMV-mpa, the Stratagene QuikChange XL
system was used as described elsewhere (Darwin et al, 2005).
To make epitope-tagged proteins, panB and fabD were amplified
by PCR from Mtb genomic DNA using primers encoding the FLAG
epitope (MDYKDDDDKI; Table I). The resulting PCR products were
cloned into pET24b(þ ), which adds a His6 tag to the cloned gene.
The pET24b(þ )-cloned inserts, including the consensus E. coli
ribosome-binding site from pET24b(þ ) and both epitope tags, were
PCR amplified and cloned into pMN402 that has the Mtb hsp60
promoter that allows expression of the cloned gene. To make the
epitope-tagged control plasmid, dlaT was PCR amplified from Mtb
genomic DNA using a 50 primer that encoded the FLAG epitope and
a 30 primer that encoded the His6 epitope with sequences exactly
as found in the fabD and panB plasmids (Table I). The amplified
product was cloned directly into pMN402.
Pfu polymerase (Stratagene) was used for all PCR-product
cloning. Restriction enzymes were purchased from New England
Biolabs. All clones were sequenced by the NYU DNA Sequencing
Core Facility to confirm the correct DNA sequence. DNA was
introduced into Mtb by electroporation as described previously
(Hatfull and Jacobs, 2000).
Nitrite survival assay and mouse infections
Nitrite survival assays and mouse infections were carried out as
described in detail elsewhere (Darwin et al, 2003, 2005). For mouse
infections, groups of mice purchased from Jackson Laboratories
Table I Bacterial strains, plasmids and primers used in this work
Strain Genotype/sequence Source or reference
Plasmids
pET24b(+) Kanr; for production of epitope-tagged protein Novagen
pMV306 Hygr; integrates at attB site on the Mtb chromosome Stover et al (1991)
pMV-mpa Hygr; pMV306 with 2.6 kb ClaI fragment containing mpa Darwin et al (2003)
pMN402 Hygr; replicating mycobacterial plasmid with gfp under the control of the BCG hsp60
promoter
Scholz et al (2000)
pMV-mpaY608F Hygr; pMV-mpa but with a Y608-F point mutation This work
pMV-mpaY608E Hygr; pMV-mpa but with a Y608-E point mutation This work
pMN-FLAG-fabD-His6 Hyg
r; pMN402 with gfp replaced by FLAG and His6-tagged fabD This work
pMN-FLAG-panB-His6 Hyg
r; pMN402 with gfp replaced by FLAG and His6-tagged panB This work
pMN-FLAG-dlaT-His6 Hyg
r; pMN402 with gfp replaced by FLAG and His6-tagged dlaT This work
E. coli
DH5a supE44 DlacU169 (j80 lacZDM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Gibco, BRL
Mtb
H37Rv wild type (WT) American Type Culture Collection 25618 ATCC
MHD4 Kanr; mpa608HFMycoMarT7 Darwin et al (2003)
MHD5 Kanr; mpa77HFMycoMarT7 (Kanr) Darwin et al (2003)
MHD18 Hygr; H37Rv pMV306 Darwin et al (2003)
MHD22 Hygr, Kanr; MHD5 pMV306 Darwin et al (2003)
MHD23 Hygr, Kanr; MHD5 pMV-mpa Darwin et al (2003)
MHD60 Hygr, Kanr; MHD5 pMV-mpaY608F This work
MHD61 Hygr, Kanr; MHD5 pMV-mpaY608E This work
MHD62 Hygr, Kanr; pafA282HFMycoMarT7 pMV306 This work
Primers
mpaY608Ffa GAGTCCAACCTCGGCCAGTTCCTGTAGGGCTCAGGCGGTCAC
mpaY608Fra GTGACCGCCTGAGCCCTACAGGAACTGGCCGAGGTTGGACTC
mpaY608Efa GATACCGAGTCCAACCTCGGCCAGGAGCTGTAGGGCTCAGGCGGTCACC
mpaY608Era GGTGACCGCCTGAGCCCTACAGCTCCTGGCCGAGGTTGGACTCGGTATC
FLAGpanBNdef2 GGAATTCCATATGGATTACAAGGATGACGACGATAAGATGTCTGAGCAGACTATCTATGGG
GCC
panBNotr2 ATAAGAATGCGGCCGCGAAACTGTGTTCGTCAGCGGGGAA
FLAGfabDNdef2 GGAATTCCATATGGATTACAAGGATGACGACGATAAGATGATTGCGTTGCTCGCACCCGGA
fabDHindIIIr2 CCCAAGCTTTAGGTTTGCCAGCTCGTCCAGGTC
PET24NheIf CTAGCTAGCCCTCTAGAAATAATTTTGTTTAAC
PET24PstIr AACTGCAGTCAGTGGTGGTGGTGGTG
RBSFLAGdlaTPacI CCTTAATTAAGAAGGAGATATACATATGGATTACAAGGATGACGACGATAAGATGGCCTTC
TCCGTCCAGATGCCG
His6dlaTPstI AACTGCAGTCAGTGGTGGTGGTGGTGGTGCAGTCCTAAATCGGCCTCGAACGC
rpoBf1 TCGTTCTCTGACCCTCGTTTC
rpoBr1 ACGTGCCCTTCTCGGTCATCA
mpaf1 CGAGAATGTCATCGTGATCG
mpar1 GGCAAGAACTCGGTCAGGTA
fabDf CAAACCGAGGGAATGTTGTC
fabDr GCTATCACACCGGCGATT
panBf GACCAAGATCCGCACCC
panBr CCTCGTAGCTGCCGAAC
aUnderlined nucleotides indicate those changed from the WT sequence.
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were infected with aerosolized Mtb using a Glas-Col Inhalation
Exposure System (Terre Haute, IN). Each mouse received about
100–200 CFU as determined by enumerating bacteria from the lungs
of three mice per Mtb strain, 24 h after infection. Mice were
humanely killed upon observation of any symptoms of illness
(hunched posture, labored breathing, thinning and ruffled fur).
Immunoblotting
Total protein lysates were prepared from equivalent cell numbers,
determined by culture optical density at wavelength 580 (OD580).
Either 5 or 10 OD equivalents were harvested. Bacteria were
collected by centrifugation and washed in 5 ml of 0.05% Tween-80
in phosphate buffered saline, resuspended in 300ml of lysis buffer
(100 mM Tris–Cl, 100 mM KCl, 1 mM EDTA, 5 mM MgCl2, pH 8) and
transferred to bead beating tubes with 200ml of zirconia silica beads
(BioSpec Products). Cells were lysed by bead beating 2–3 times in
a BioSpec Mini Bead Beater for 30 s. Total cell lysate (150ml) was
mixed with 50 ml of protein sample buffer. The samples were boiled
at 1001C for 10 min and equal volumes representing equivalent cell
numbers were separated by SDS–PAGE in a 10% gel.
For immunodetection, FLAG antibodies were purchased from
Sigma (St Louis, MO) and were used according to the manufac-
turer’s instructions. Polyclonal antibodies to Mpa-His6, PrcB-His6
and DlaT-His6 were used as described elsewhere (Darwin et al,
2005; Tian et al, 2005; Lin et al, 2006). For all immunoblots,
experimental membranes were stripped and incubated with anti-
DlaT to check equivalent loading of samples (Darwin et al, 2005;
Tian et al, 2005). Horseradish peroxidase (HRP) coupled anti-rabbit
secondary antibodies were used according to the manufacturer’s
instructions (Amersham). Detection of HRP was performed using
either SuperSignal West Pico or West Femto Chemiluminescent
Substrate (Pierce).
QRTPCR
Mtb strains were grown to late logarithmic phase (OD580B1.0) in
7H9þADN broth in the presence of the appropriate antibiotics.
Cultures were added to an equal volume of 5 M guanidium
isothiocyanate, 0.5% sodium-N-lauryl sarcosine, 25 mM tri-sodium
citrate, 0.1 M b-mercaptoethanol to stop transcription and cells were
harvested by centrifugation. RNA was extracted from the bacterial
pellets using TRIzol Reagent (Invitrogen). The pellets were
resuspended in 1.2 ml TRIzol Reagent and the samples were lysed
by bead beating as described above. The remaining RNA purifica-
tion steps were carried out as described in the TRIzol protocol
and repeated to ensure removal of genomic DNA. The Reverse
Transcription System (Promega) was used to synthesize cDNA from
100 ng of Mtb RNA with 4 ng of random hexamers (Amersham) to
prime synthesis. The cDNA equivalent ofB1.9 ng of total Mtb RNA
was analyzed by quantitative PCR using Platinum SYBR Green
qPCR SuperMix UDG (Invitrogen) in a DNA Engine Opticon 2
Continuous Fluorescence Detection System (MJ Research) (for
primers, see Table I). For quantification, transcript copy numbers
were determined by comparison to a standard curve of Mtb
genomic DNA. The relative amounts of each transcript were
normalized to that of rpoB, a control gene that is not differentially
regulated in any of our Mtb strains (unpublished data). cDNA were
synthesized from at least two biologically replicate RNA samples
and QRTPCR was performed twice, in triplicate, for each cDNA.
Proteomics analysis
Two-dimensional SDS–PAGE analysis of filtered (0.22mm) soluble
Mtb lysates was performed at Kendrick Labs (www.kendricklabs.
com). Gels were silver stained and protein spots were excised and
shipped by Kendrick Labs to the Columbia University Protein Core
Facility for MALDI-TOF analysis.
Mycolic acid biosynthesis
Mtb cultures were grown to mid-log phase. In total, 5mCi of 14C-
acetate or 14C-propionate were added to 10 ml cultures and
incubated for 16 h at 371C. Mycolic acids were extracted from
acetate or propionate fed culture pellets using the protocols
described in the previous study (Phetsuksiri et al, 1999). In brief,
the cells were harvested by centrifugation at 3000 g. The cell pellets
were treated with 2 ml of 20% tetrabutyl-ammonium hydroxide at
1001C. After 12–14 h, 2 ml of dichloromethane and 300ml of methyl
iodide was added. All the tubes were mixed by gentle vortexing and
incubated for 1 h at room temperature. After centrifugation at
2000 r.p.m. for 10 min, the aqueous layer was removed. The organic
phase was washed twice with acidified water before drying under
vacuum. The pellet was dissolved in 4 ml diethylether and liquid
phase was removed by aspiration. The dried residue was dissolved
in 200 ml of dichloromethane and quantified by scintillation
counting. Approximately 10 000 c.p.m. per sample was spotted on
silica gel 60 F254 TLC plates (Merck) and developed thrice in
hexane:ethyl acetate (95:5, v/v).
Methylated (sulpholipid) lipid biosynthesis
Mtb cultures were grown to mid-log phase. 14C-propionate (5mCi)
was added to 10 ml cultures and incubation continued for 16 h at
371C. Extractable lipids were isolated from cell pellets of propionate
fed cultures using previously described methodologies (Converse
et al, 2003). The harvested cell pellet was treated with 0.5 ml
of chloroform:methanol (1:2, v/v) and vortexed. Acidified water
(0.5 ml) was then added and organic and aqueous layers were
separated by centrifugation for 30 s. The lower layer (organic
chloroform layer) was transferred to a fresh glass tube and dried in
a vacuum concentrator. The residue was resuspended in chloroform
and approximately 25 000 c.p.m. per sample was spotted per
sample. Lipids resolved on silica gel 60 A˚ with fluorescent indicator
(Catalogue No. 4802-400, Whatman) or silica gel 60 A˚ F254(Cata-
logue No. 1.05554.0007, Merck), developed in chloroform:metha-
nol:water (60:30:6, v/v) at ambient temperature.
Extraction of apolar lipids
Mtb cultures were grown to mid-log phase. 14C-palmitate (5mCi)
was added to 10 ml cultures and incubation continued for 16 h at
371C. The 14C-palmitate-labelled apolar lipids were extracted by
adding 2 ml of chloroform/0.3% NaCl (100/10; v/v) and 2 ml of
petroleum ether to the cell pellet followed by stirring for 30 min.
After centrifugation, the upper petroleum ether layer was removed,
and 2 ml of petroleum ether was added to the lower phase, and the
process was repeated. The combined petroleum ether extracts were
then evaporated under nitrogen to yield apolar lipids that were
resuspended in CH2Cl2 and analyzed by toluene/acetone (99/1;
v/v) (Kremer et al, 2005). The wax esters were resolved on silica gel
60 A˚ F254 (Catalogue No. 1.05554.0007, Merck) and developed in
hexanes:diethyl ether:acetic acid (80:20:1, v/v) (Kalscheuer and
Steinbuchel, 2003).
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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